Compared to the standard shot, the mRNA vaccine had an overall vaccine efficacy that was 26.6 percent higher, and 27.4 ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

In adults 50 and older, Moderna’s flu shot was more than 26% better than an unspecified commercial vaccine. In May, the ...

The biotechnology company’s messenger RNA flu vaccine candidate showed positive results in a late-stage trial.

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing.

The vaccine, called mRNA-1010, is designed to target four lineages of influenza viruses that circulate seasonally each year, just like the current quadrivalent flu vaccines on the market.

In a recent study, a 20-valent mRNA vaccine elicited immunity against influenza virus in mice. These results, combined with the success of mRNA vaccines against Covid-19, augur well for a new type ...

Moderna has commenced human trials testing an mRNA influenza vaccine targeting four separate viral strains. Building on its successful mRNA COVID-19 vaccine, the company is planning to develop a ...

The experimental mRNA-lipid nanoparticle vaccine developed by Hensley and colleagues encoded hemagglutinin (HA) antigens from all 20 known influenza A and B virus subtypes.

The Cambridge, Mass. company said Tuesday it will receive $176 million from HHS' BARDA to accelerate development of mRNA-based pandemic influenza vaccines.